42 results
DEFM14A
SQZB
SQZ Biotechnologies Co
23 Jan 24
Proxy related to merger
4:31pm
, without independent verification or any responsibility therefor, the accuracy and completeness of the financial, legal, regulatory, tax, accounting … not have any obligation or responsibility to update, revise or reaffirm its opinion based on circumstances, developments or events occurring after
PREM14A
SQZB
SQZ Biotechnologies Co
12 Jan 24
Preliminary proxy related to merger
8:57am
Partners assumed, without independent verification or any responsibility therefor, the accuracy and completeness of the financial, legal, regulatory, tax … , and Leerink Partners does not have any obligation or responsibility to update, revise or reaffirm its opinion based on circumstances, developments or events
8-K
EX-2.1
SQZB
SQZ Biotechnologies Co
22 Dec 23
Entry into a Material Definitive Agreement
5:18pm
”), will be assumed by Purchaser. The Excluded Liabilities will remain the sole responsibility of and will be retained, paid, performed and discharged solely … of the Transferred Assets after the Closing.
Seller hereby disclaims all Liability and responsibility for any representation, warranty, statement
PRE 14A
SQZB
SQZ Biotechnologies Co
10 Apr 23
Preliminary proxy
4:31pm
to joining Pliant, Dr. Coulie cofounded ActoGeniX N.V., a biopharmaceutical company, and held roles of increasing responsibility there, including as Vice … is responsible for monitoring and assessing strategic risk exposure, and our Audit Committee has the responsibility to discuss the Company’s policies
8-K
EX-10.1
aqfsc t6t5usd
11 Jul 22
SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer
4:49pm
S-3
EX-4.3
a77wldg5re3e69zfb oz
12 Nov 21
Shelf registration
12:00am
S-3
0o5hi5nu hm
12 Nov 21
Shelf registration
12:00am
S-3
EX-1.2
k665tise 9j6lvt0
12 Nov 21
Shelf registration
12:00am
DEF 14A
f2u9pe7
26 Apr 21
Definitive proxy
5:00pm
10-K
33gvk u19
18 Mar 21
Annual report
6:31am
424B4
92952italu5dp
12 Feb 21
Prospectus supplement with pricing info
5:10pm